Meta-Analysis
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2020; 11(10): 468-480
Published online Oct 15, 2020. doi: 10.4239/wjd.v11.i10.468
Prevalence and impact of diabetes in patients with COVID-19 in China
Min Du, Yu-Xin Lin, Wen-Xin Yan, Li-Yuan Tao, Min Liu, Jue Liu
Min Du, Yu-Xin Lin, Wen-Xin Yan, Min Liu, Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
Li-Yuan Tao, Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100083, China
Author contributions: Liu J conceived and designed the study; Du M and Yan WX carried out the literature searches; Du M, Yan WX, and Lin YX extracted the data; Du M, Lin YX, and Yan WX assessed the study quality; Du M performed the statistical analysis; Du M and Liu J wrote the manuscript; Liu J, Du M, Liu Min, and Tao LY revised the manuscript.
Supported by the National Natural Science Foundation of China, No. 71934002.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
PRISMA 2009 Checklist statement: The guidelines of the PRISMA 2009 statement have been adopted.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jue Liu, PhD, Associate Professor, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, No. 38 Xueyuan Road, Haidian District, Beijing 100191, China. jueliu@bjmu.edu.cn
Received: April 19, 2020
Peer-review started: April 19, 2020
First decision: May 20, 2020
Revised: May 25, 2020
Accepted: August 25, 2020
Article in press: August 25, 2020
Published online: October 15, 2020
Processing time: 177 Days and 18.5 Hours
Core Tip

Core Tip: At present, the prevalence and impact of diabetes in patients with coronavirus disease 2019 (COVID-19) have not been systematically reviewed in China. This meta-analysis for the first time focused on the pooled prevalence of diabetes among COVID-19 patients and its impact on clinical outcomes (ICU admission, severity, and death) in China. The analysis showed that the pooled prevalence of diabetes was 10% [95% confidence interval (CI): 7%-15%] in COVID-19 patients. Besides, the risks of severe cases (risk ratio = 2.13, 95%CI: 1.76-2.56, I2 = 49%, P = 0.007) and deaths (risk ratio = 3.16, 95%CI: 2.64-3.78, I2 = 34%, P = 0.20) were both higher in COVID-19 patients with diabetes compared with those without. Our findings highlight the need for targeted intervention on diabetes among COVID-19 patients.